摘要目的了解恶性肿瘤患者血浆组织因子(TF)和尿激酶型纤溶酶原激活物(u-PAR)系统的改变及其与肿瘤种类、病理分型和转移情况的关系.方法运用ELISA法检测76例恶性及24例良性肿瘤患者血浆TF及其抑制物(TFPI),u-PAR及其受体(u-PAR)水平.结果恶性肿瘤患者血浆TF和u-PAR水平较良性肿瘤组及正常对照组显著升高.食管癌及胃癌患者血浆u-PA显著升高.除TFPI外,其余三项指标与患者的病理分型无关.局部侵润、局部淋巴结受累及远处转移患者血浆u-PA水平与无上述情况的患者组存在明显差异,而u-PAR在局部淋巴结受累和远处转移患者较无上述情况的患者组显著升高.结论恶性肿瘤患者体内存在着TF和u-PAR系统的激活.U-PA及其受体的检测可提示疾病的进程 .

abstractsObjective To evaluate variations in the plasma tissue factor (TF) and urokinase type plasm inogen activator (u-PA) system and their relationship with clinical cancer type , pathological classification and metastatic status in cancer patients. Methods Plasma levels of TF and its inhibitor (TFPI), as well as u-PA and its receptor (u-PAR) were measured using ELISA in 76 patients with malignant tumors and 24 patients with benign tumors.Results Plasma levels of TF and u-PAR in the malignant tumor group were significantly h igher than those of the benign tumor group and the normal control. U-PA and u -PAR increased significantly in patients with esophageal and gastric cancer. H owever, most of these parameters except TFPI did not vary according to patholo gical classification. A significant elevation was evident in patients with loc al infiltration, lymph node involvement and distal metastasis, while u-PAR only increased in the latter two categories. Conclusions Both the TF and u-PA systems are activated in cancer patients. U-PA and its r eceptor might prove to be a clinically useful marker for disease progression.